Clinical Trials
11
Active:7
Completed:3
Trial Phases
3 Phases
Phase 1:2
Phase 2:1
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (50.0%)Phase 2
1 (25.0%)Phase 3
1 (25.0%)OCR002-SP103 - Oral Immediate Release Study
Phase 1
Completed
- Conditions
- Cirrhosis
- Interventions
- Drug: OCR-002 IV SolutionDrug: OCR-002 IR Oral TabletDrug: OCR-002 Oral Solution
- First Posted Date
- 2019-02-20
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- Ocera Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03846843
- Locations
- 🇺🇸
Southern California Research Center, Coronado, California, United States
Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
Phase 2
Completed
- Conditions
- Hepatic EncephalopathyAcute Episode of Overt Hepatic Encephalopathy
- Interventions
- Drug: placebo intravenous infusion
- First Posted Date
- 2013-10-21
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Ocera Therapeutics, Inc.
- Target Recruit Count
- 231
- Registration Number
- NCT01966419
Emergency Use of OCR-002 in Acute Liver Failure (ALF)
- Conditions
- Acute Liver Failure
- First Posted Date
- 2012-07-06
- Last Posted Date
- 2021-06-24
- Lead Sponsor
- Ocera Therapeutics, Inc.
- Registration Number
- NCT01634230
- Locations
- 🇺🇸
University of Arkansas, Little Rock, Arkansas, United States
News
No news found